Multi-year order boosts stock prices by 100% – analysts
Mumbai’s Remedium Lifecare Limited reported on 18 Feb a Rs.182 crore multi-year contract with a major UK-based pharmaceutical distribution company for supplying APIs, Intermediates and Specialty Chemicals.
This groundbreaking deal has placed Remedium Lifecare among the renowned players in the global supply chain of pharmaceutical products, say market analysts, predicting a potential for an exponential rise in the company’s stock prices https://www.bseindia.com/.
Remedium’s financial fundamentals, having a PE ratio of just 11 compared to the pharma sector 60, have made this development even more noteworthy, they said https://www.nseindia.com/.
The deal can increase the company’s stock prices by a 100%, the analysts added https://fieo.org/.
Remedium’s zero debt status and robust 65% promoter holding add to investor confidence. The company’s strategic growth through API manufacturing supported by state-of-the-art facilities in Hyderabad demonstrates its growth into a manufacturer from just a trader.
While this partnership with this major UK-based pharmaceutical distribution company presents a range of growth opportunities for Remedium Lifecare, investors should note that success comes from compliance with regulatory standards, and conducting research before investments is crucial http://ipapharma.net.
However, with a presence in 27 countries, operating debt-free and manufacturing with zero defects, the company has a high chance of successfully capitalizing on this opportunity. Fiinews.com
